Full Press Release Details
Protalix BioTherapeutics to Present at the UBS Global Life Sciences Conference
CARMIEL, Israel, September 13, 2010 (PR NEWSWIRE) Protalix BioTherapeutics, Inc. (NYSE-AMEX:
PLX, TASE:PLX), announced today that Dr. David Aviezer, Protalix s president and CEO, will present
at the UBS Global Life Sciences Conference on September 20, 2010 at 10:30 AM ET. The conference is
being held September 20 22, 2010 at the Grand Hyatt Hotel in New York City.
An audio webcast of the presentation will be available on Protalix s website,
www.protalix.com, on the event calendar page.
Protalix is a biopharmaceutical company focused on the development and commercialization of
proprietary recombinant therapeutic proteins expressed through its proprietary plant cell based
expression system. Protalix s ProCellEx presents a proprietary method for the expression of
recombinant proteins that Protalix believes will allow for the cost-effective, industrial-scale
production of recombinant therapeutic proteins in an environment free of mammalian components and
viruses. Protalix is also advancing additional recombinant biopharmaceutical drug development
programs. Taliglucerase alfa is an enzyme replacement therapy in development under a Special
Protocol Assessment with the FDA for Gaucher disease. The Company s new drug application (NDA) for
taliglucerase alfa has been accepted by the U.S. Food and Drug Administration (FDA) and granted a
Prescription Drug User Fee Act (PDUFA) action date of February 25, 2011.
The Trout Group, LLC
Telephone: 646-378-2927
Email: mnanus@troutgroup.com